Dr. Reddy's Laboratories cash flow

Latest FY26

Cash from operations: ₹5,674cr+22.2% on FY25
Capital spending: ₹3,841cr+11.6% on FY25
Free cash flow: ₹1,833cr+52.4% on FY25
Cash from financing: ₹829cr−30.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	2,059	1,704	1,470	1,250
	—	352	169	0.3	69.9
	—	374	283	171	143
	—	0.0	−268	−228	−118
	—	−236	−355	−315	−87.6
	—	32.6	42.4	40.7	39.7
	—	−52.9	21.1	−53.3	−92.5
	—	69.0	16.1	27.5	507
	—	−255	−151	−90.0	20.8
	—	−860	−1,275	−1,845	−265
	—	−672	−1,028	−805	−575
	—	0.0	−729	286	52.8
	—	179	0.0	0.0	0.0
	—	279	34.0	0.0	2.3
	—	0.0	0.0	346	0.0
	—	752	522	356	0.0
Cash from operating activities
	3,524	5,379	7,658	7,186	6,012
	—	2,020	−1,016	−638	947
	—	7,399	6,642	6,548	6,959
	—	−373	0.0	0.0	0.0
	—	1,353	1,999	2,005	1,071
	—	5,674	4,643	4,543	5,887
Cash from investing activities
	—	2,331	2,750	1,640	1,132
	—	1,510	689	1,103	754
	—	30.9	51.2	106	8.2
	—	140	0.0	0.0	0.0
	—	0.0	73.2	2.1	0.0
	—	4,672	25,446	14,549	13,617
	—	1,960	28,663	12,978	11,281
	—	315	5,310	0.0	0.0
	—	5.1	31.7	1.2	0.0
	—	0.0	0.0	44.5	0.0
	—	152	337	134	77.7
	—	−6,549	−5,102	−4,028	−4,137
Cash from financing activities
	—	39.7	19.3	80.5	15.7
	—	0.0	139	0.0	0.0
	—	2,026	2,449	929	0.0
	—	0.1	0.0	380	1,938
	—	126	129	115	102
	—	444	348	227	185
	—	666	666	665	498
	—	0.0	0.0	0.0	21.1
	—	829	1,186	−376	−2,686
	—	−46.6	726	139	−936
	—	124	22.4	−5.9	28.6
	—	77.5	749	133	−907
	—	—	—	711	578
Reference items
	4,861	6,454	8,547	7,933	6,349
	14.7%	19.2%	26.2%	28.3%	25.7%
	1,833	1,833	1,203	1,800	4,001
	—	3,498	3,387	1,878	—
	₹21.95	₹21.95	₹14.41	₹21.55	₹47.91
	60.83×	—	—	—	—
	—	1.36×	0.81×	0.81×	1.31×
	—	1,353	1,999	2,005	1,071
	—	444	348	227	185

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹1.12L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	1,250.2	1,470.0	1,703.7	2,058.8	—
+ Impairment Loss / (Reversal)	69.9	0.3	169.3	351.8	—
+ Finance Costs	142.8	171.1	282.9	373.8	—
+ Interest Income	-118.0	-227.8	-267.7	0.0	—
+ Fair Value (Gains) / Losses	-87.6	-314.9	-355.4	-235.9	—
+ Share-based Payments	39.7	40.7	42.4	32.6	—
+ Unrealised FX (Gain) / Loss	-92.5	-53.3	21.1	-52.9	—
+ Other Non-cash Items	507.4	27.5	16.1	69.0	—
+ Other — Cash Effects are Investing / Financing	20.8	-90.0	-151.2	-254.7	—
Changes in Working Capital
+ Inventories	-265.4	-1,844.5	-1,275.3	-860.1	—
+ Trade Receivables — Current	-575.2	-805.4	-1,028.3	-672.2	—
+ Other Current Assets	52.8	285.7	-729.3	0.0	—
+ Other Non-current Assets	0.0	0.0	0.0	178.7	—
+ Trade Payables — Current	2.3	0.0	34.0	279.0	—
+ Trade Payables — Non-current	0.0	346.0	0.0	0.0	—
+ Provisions — Current	0.0	356.3	522.0	751.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	6,011.5	7,186.3	7,657.8	5,379.3	3,523.8
+ Total Adjustments (incl. Working Capital)	947.2	-638.3	-1,015.7	2,019.6	—
Cash from Operations (pre-tax)	6,958.7	6,548.0	6,642.1	7,398.9	—
+ Interest Received — Operating	0.0	0.0	0.0	-372.6	—
+ Income Taxes Paid	1,071.4	2,004.7	1,999.3	1,352.6	—
Cash from Operating Activities	5,887.3	4,543.3	4,642.8	5,673.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	1,132.3	1,640.3	2,750.4	2,330.6	—
+ Acq of Intangible Assets	754.1	1,103.2	689.4	1,509.9	—
+ Disp of Fixed Assets	8.2	106.4	51.2	30.9	—
+ Disp of Intangible Assets	0.0	0.0	0.0	140.1	—
+ Disp of Intangibles under Development	0.0	2.1	73.2	0.0	—
+ Purchase of Investments (Equity / Debt)	13,617.1	14,548.8	25,445.8	4,671.8	—
+ Sale of Investments (Equity / Debt)	11,280.5	12,978.4	28,663.2	1,960.2	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	5,309.6	315.2	—
+ Investment in Partnership Firms / LLPs	0.0	1.2	31.7	5.1	—
+ Dividends Received — Investing	0.0	44.5	0.0	0.0	—
+ Interest Received — Investing	77.7	133.8	337.2	152.1	—
Cash from Investing Activities	-4,137.1	-4,028.3	-5,102.1	-6,549.3	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	15.7	80.5	19.3	39.7	—
+ Buyback / Redemption of Own Shares	0.0	0.0	138.9	0.0	—
+ Proceeds from Borrowings	0.0	929.3	2,449.0	2,025.7	—
+ Repayment of Borrowings	1,938.2	380.0	0.0	0.1	—
+ Payment of Lease Liabilities	101.5	114.7	129.4	126.3	—
+ Interest Paid	185.3	226.6	348.3	444.1	—
+ Dividends Paid	497.9	664.8	666.2	665.9	—
+ Other Inflows / (Outflows) — Financing	21.1	0.0	0.0	0.0	—
Cash from Financing Activities	-2,686.1	-376.3	1,185.5	829.0	—
Net Changes in Cash (pre-FX)	-935.9	138.7	726.2	-46.6	—
+ Effect of FX Rate Changes on Cash	28.6	-5.9	22.4	124.1	—
Net Changes in Cash	-907.3	132.8	748.6	77.5	—
Closing Cash	577.9	710.7	—	—	—
Reference Items
EBITDA	6,349.0	7,933.1	8,547.1	6,453.5	4,860.5
EBITDA Margin %	25.74	28.32	26.18	19.15	14.69
Free Cash Flow (CFO − Capex)	4,000.9	1,799.8	1,203.0	1,833.2	1,833.2
Free Cash Flow to Equity	—	1,878.3	3,386.9	3,498.1	—
Free Cash Flow per Basic Share	47.91	21.55	14.41	21.95	21.95
Price to Free Cash Flow	—	—	—	—	60.83
Cash Flow to Net Income	1.31	0.81	0.81	1.36	—
Cash Paid for Taxes	1,071.4	2,004.7	1,999.3	1,352.6	—
Cash Paid for Interest	185.3	226.6	348.3	444.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.